‘Global Translational Regenerative Medicine Market Worth $14.5bn In 2021’ Says Visiongain Report

22 August 2018
Pharma

Visiongain’s new report Translational Regenerative Medicine Market Report : Stem Cell Therapies, Tissue Engineered Products, Gene Therapies indicates that the Global Translational Regenerative Medicine Market will see $14.5bn in spending in 2021.

The Global Translational Regenerative Medicine market is expected to grow significantly over the forecast period. The Global Translational Regenerative Medicine market was valued at $5.8bn in 2016. Visiongain forecasts this market to increase to $14.5bn in 2021. The market is estimated to grow at a CAGR of 19.9% in the first half of the forecast period and 17.7% from 2016 to 2027.

The lead analyst of the report said: “Growth in the global TRM market will be fuelled particularly by stem cell therapies and tissue engineering advancements, as well as the emergence of commercial gene therapy products. The improvements in regulation of stem cell research on a regional level will increase its attractiveness. We note that advancements such as 3D bioprinting should enable the development of tissues which can be used for toxicology testing purposes.

Furthermore, strong government support for regenerative medicine particularly in countries such as China and South Korea, as well as the accelerated regulatory pathway for regenerative medicine in Japan will fuel growth in stem cell therapies.”

The 316-page report contains 107 tables and 66 figures that add visual analysis in order to explain the developing trends within the Global Translational Regenerative Medicine Market.

Visiongain provides revenue forecasts for the period 2017-2027 for the global market as well as the leading submarkets: Stem Cell Therapies, Tissue Engineered Products and Gene Therapies.

Furthermore, this report provides revenue forecasts for these leading products: Osteocel Plus, Trinity ELITE, TEMCELL /Prochymalm, Apligraf, Dermagraft, Epifix, ReCell, Neovasculgen, Glybera (alipogene tiparvovec), IMLYGIC (talimogene laherparepvec).

The 316-page report offers market forecasts and analysis for: the US, Europe, Asia-Pacific and the Rest of the World. In addition, this report discusses the leading companies in the Translational Regenerative Medicine Market.

The Global Translational Regenerative Medicine Market Prospects 2017-2027: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies report will be of value to anyone who wants to better understand the translational regenerative medicine market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the translational regenerative medicine industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever